Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Poxel stock

POXEL.PA
FR0012432516
A14M04

Price

0.35
Today +/-
-0.01
Today %
-3.36 %
P

Poxel stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Poxel stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Poxel stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Poxel stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Poxel's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Poxel Stock Price History

DatePoxel Price
10/2/20240.35 undefined
10/1/20240.36 undefined
9/30/20240.41 undefined
9/27/20240.55 undefined
9/26/20240.53 undefined
9/25/20240.53 undefined
9/24/20240.53 undefined
9/23/20240.54 undefined
9/20/20240.57 undefined
9/19/20240.55 undefined
9/18/20240.53 undefined
9/17/20240.52 undefined
9/16/20240.53 undefined
9/13/20240.55 undefined
9/12/20240.56 undefined
9/11/20240.57 undefined
9/10/20240.59 undefined
9/9/20240.56 undefined
9/6/20240.56 undefined
9/5/20240.57 undefined

Poxel Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Poxel, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Poxel from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Poxel’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Poxel. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Poxel’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Poxel’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Poxel’s growth potential.

Poxel Revenue, EBIT and net profit per share

DatePoxel RevenuePoxel EBITPoxel Net Income
2026e39.27 M undefined-26.55 M undefined-92.42 M undefined
2025e11.95 M undefined-32.24 M undefined-69.23 M undefined
2024e58.5 M undefined25.85 M undefined-62.66 M undefined
2023e1.65 M undefined-25.24 M undefined-39.59 M undefined
2022674,000 undefined-21.89 M undefined-31.4 M undefined
202113.4 M undefined-22.46 M undefined-23.76 M undefined
20206.81 M undefined-29.82 M undefined-31.83 M undefined
201926.56 M undefined-24.67 M undefined-25.74 M undefined
201862.38 M undefined314,000 undefined1.3 M undefined
20175.29 M undefined-21.9 M undefined-22.3 M undefined
201670,270 undefined-24.28 M undefined-24.48 M undefined
201559,650 undefined-11.34 M undefined-12.24 M undefined
20140 undefined-6.9 M undefined-14.08 M undefined
20130 undefined-7.27 M undefined-20.45 M undefined
20120 undefined-7.12 M undefined-7.14 M undefined
20110 undefined-8.68 M undefined-8.62 M undefined

Poxel Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2011201220132014201520162017201820192020202120222023e2024e2025e2026e
0000005622661301581139
-------1,140.00-58.06-76.92116.67--5,700.00-81.03254.55
---------100.00100.00-----
00000000061300000
-8-7-7-6-11-24-210-24-29-22-21-2525-32-26
-------420.00--92.31-483.33-169.23--2,500.0043.10-290.91-66.67
-8,000-7,000-20,000-14,000-12,000-24,000-22,0001,000-25,000-31,000-23,000-31,000-39,000-62,000-69,000-92,000
--12.50185.71-30.00-14.29100.00-8.33-104.55-2,600.0024.00-25.8134.7825.8158.9711.2933.33
12.5112.5112.5112.5119.4821.0723.0324.8325.9427.5328.6429.080000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Poxel Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Poxel is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201120122013201420152016201720182019202020212022
                       
6.54.97.9710.3045.5754.1666.7437.1940.232.2913.06
000000.044.914.266.590.280.050.39
004.142.803.856.636.198.214.533.242.4
000000000000
0.100.120.400.150.551.080.90.950.760.73
6.64.912.2413.5049.666.2588.2752.8945.9636.3416.57
000.02000.150.140.32.322.221.721.32
008.623000556.76356.11372477246206211
00000000003.242.4
000000016.5816.6116.6416.6316.61
000000000000
0000000000-00
000.030.300.70.517.2519.4119.1121.7920.54
6.64.912.2713.8050.366.75105.5272.365.0858.1337.11
                       
2002001953000459.01462.55517521570574603
0.30.30.3530.40106.38106.95128129.02145.8524.7826.67
6.8-0.2-20.56-33.20-67.46-88.09-72.73-90.31-119.61-17.43-46.07
0000000-5-9674277558
000000000000
7.30.3-20.01-2.5039.3919.3355.7839.1426.888.21-18.24
1.11.51.961.104.923.258.6510.223.073.672.94
0.43.724.40.300.470.91.132.122.122.272.43
11.62.54203.6941.5625.449.578.414.913.83
0000000.75000.3404.57
0.20.32.568.601.010.1813.878.942.535.0513.65
2.77.131.4612010.0846.6449.130.8516.4615.927.42
0.10.70.733.900.710.560.361.8420.9930.0925.22
000000000000
010085.315000131.21229.88279469753688318
0.10.80.814.400.840.790.642.3121.7430.7825.54
2.87.932.2816.4010.9247.4349.7333.1638.246.6852.96
10.18.212.2713.9050.366.75105.5272.365.0854.8934.71
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Poxel provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Poxel's financial health and stability.

Assets

Poxel's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Poxel must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Poxel after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Poxel's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-8-7-20-14-12-24-2213-25-31-23-31
000000000000
000000000000
01000428-19-201-3
00137111125412
0000000001,0001,0001,000
000000000000
-8-5-6-6-10-188-4-25-25-16-21
0000000-70000
0000000-70000
000000000000
000000000000
0394-1-2-113-512103
5003442401211600
54984221025-42892
-----------1.00-1.00
000000000000
-2-132323713-293-7-19
-8.29-5.65-6.69-6.1-10.21-18.878.09-12.62-25.81-26.03-16.94-21.84
000000000000

Poxel stock margins

The Poxel margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Poxel. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Poxel.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Poxel's sales revenue. A higher gross margin percentage indicates that the Poxel retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Poxel's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Poxel's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Poxel's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Poxel. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Poxel's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Poxel Margin History

Poxel Gross marginPoxel Profit marginPoxel EBIT marginPoxel Profit margin
2026e0.3 %-67.6 %-235.32 %
2025e0.3 %-269.83 %-579.43 %
2024e0.3 %44.19 %-107.11 %
2023e0.3 %-1,531.25 %-2,402.08 %
20220.3 %-3,247.77 %-4,658.46 %
202199.56 %-167.67 %-177.38 %
2020100 %-438.13 %-467.69 %
20190.3 %-92.9 %-96.93 %
20180.3 %0.5 %2.09 %
20170.3 %-414.02 %-421.5 %
2016100 %-34,555.74 %-34,841.22 %
2015100 %-19,004.11 %-20,521.39 %
20140.3 %0 %0 %
20130.3 %0 %0 %
20120.3 %0 %0 %
20110.3 %0 %0 %

Poxel Stock Sales Revenue, EBIT, Earnings per Share

The Poxel earnings per share therefore indicates how much revenue Poxel has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Poxel earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Poxel's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Poxel’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Poxel's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Poxel Revenue, EBIT and net profit per share

DatePoxel Sales per SharePoxel EBIT per sharePoxel Earnings per Share
2026e0.74 undefined0 undefined-1.74 undefined
2025e0.22 undefined0 undefined-1.3 undefined
2024e1.1 undefined0 undefined-1.18 undefined
2023e0.03 undefined0 undefined-0.75 undefined
20220.02 undefined-0.75 undefined-1.08 undefined
20210.47 undefined-0.78 undefined-0.83 undefined
20200.25 undefined-1.08 undefined-1.16 undefined
20191.02 undefined-0.95 undefined-0.99 undefined
20182.51 undefined0.01 undefined0.05 undefined
20170.23 undefined-0.95 undefined-0.97 undefined
20160 undefined-1.15 undefined-1.16 undefined
20150 undefined-0.58 undefined-0.63 undefined
20140 undefined-0.55 undefined-1.13 undefined
20130 undefined-0.58 undefined-1.63 undefined
20120 undefined-0.57 undefined-0.57 undefined
20110 undefined-0.69 undefined-0.69 undefined

Poxel business model

Poxel SA is a biopharmaceutical company focused on developing drugs for the treatment of metabolic disorders, particularly type 2 diabetes. The company was founded in Lyon, France, in 2009. Poxel SA's business model is based on the targeted development of drugs for the treatment of metabolic disorders with high medical demand and large market potential. The company focuses on identifying drug candidates that are highly specific and effective while also having a favorable safety profile. Poxel SA collaborates closely with academic research and the industry to leverage the latest knowledge and technologies in drug development. Over the years, Poxel SA has become a leading company in metabolism medicine, with an extensive product pipeline of promising drug candidates. The product range includes both preclinical and clinical candidates, as well as products in advanced stages of clinical development. One of Poxel SA's main products is Imeglimin, a drug for the treatment of type 2 diabetes. Imeglimin is a new active ingredient that acts on the metabolic disorder in a novel way and improves the body's glucose metabolism. The drug is currently in the final phase of clinical development and has shown promising results in previous studies. Another promising product from Poxel SA is PXL770, a drug for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). PXL770 is a novel active ingredient that acts on the body's AMP-activated protein kinase system and regulates lipid and glucose metabolism. The drug is still in the clinical development phase but has already shown promising results. Another promising product group from Poxel SA are the adenosine monophosphate (AMP) activators, which are also being developed for the treatment of metabolic disorders such as type 2 diabetes and fatty liver disease. The AMP activators act on the body's AMP-activated protein kinase system and regulate lipid and glucose metabolism. Poxel SA also works closely with partners in the pharmaceutical industry to develop and bring innovative drug candidates to the market. The company has partnerships with leading companies such as Sumitomo Dainippon Pharma, Roivant Sciences, and Servier to expand and diversify its product pipeline. Overall, Poxel SA is an emerging company in metabolism medicine, focusing on the development of innovative drugs for the treatment of metabolic disorders. With a strong product pipeline and proven collaboration with academia and the industry, Poxel SA is a promising player in this growing market. Poxel is one of the most popular companies on Eulerpool.com.

Poxel SWOT Analysis

Strengths

Poxel SA has several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with deep knowledge of the pharmaceutical industry. This allows them to make informed and strategic decisions. Secondly, Poxel SA has a robust pipeline of innovative and potentially groundbreaking drugs, which can provide a competitive edge in the market. Additionally, the company has established strong relationships with key partners and collaborators, enabling them to effectively leverage resources and expertise.

Weaknesses

While Poxel SA has many strengths, it also faces certain weaknesses that need to be addressed. One of the weaknesses is the company's heavy reliance on a limited number of products for revenue generation. This concentration of revenue creates a vulnerability for Poxel SA, as adverse events or market changes related to these products could significantly impact its financial performance. Moreover, Poxel SA has a relatively small market share compared to its competitors, which limits its bargaining power with suppliers.

Opportunities

Poxel SA operates in an industry with several growth opportunities. Firstly, there is a rising global demand for innovative pharmaceuticals, especially in the field of metabolic disorders. Poxel SA can take advantage of this demand by leveraging its expertise and developing effective drugs to address this unmet need. Furthermore, the company can explore partnerships and collaborations to expand its market reach and penetrate new regions. Additionally, advancements in technology and research provide Poxel SA with the opportunity to develop more personalized and targeted therapies, leading to improved patient outcomes.

Threats

Like any other company in the pharmaceutical industry, Poxel SA also faces threats that could impact its future growth and profitability. One of the major threats is the stringent regulatory environment, which can delay the approval and commercialization of new drugs. Additionally, the industry is highly competitive, with numerous companies vying for market share. This intensifies the need for Poxel SA to continuously innovate and differentiate its products. Economic downturns and fluctuations in currency exchange rates can also pose threats to the company's financial stability.

Poxel Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Poxel historical P/E ratio, EBIT multiple, and P/S ratio

Poxel shares outstanding

The number of shares was Poxel in 2023 — This indicates how many shares 29.077 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Poxel earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Poxel's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Poxel’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Poxel's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Poxel.

Poxel latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.43 -0.42  (2.92 %)2023 Q2
12/31/2022-0.24 -0.23  (2.93 %)2022 Q4
1

Eulerpool ESG Scorecard© for the Poxel stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

19

👫 Social

99

🏛️ Governance

61

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
1.78
Scope 3 - Indirect emissions within the value chain
40
Total CO₂ emissions
1.78
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees69
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Poxel shareholders

%
Name
Stocks
Change
Date
8.02209 % Bpifrance Participations S.A.4,262,445-45,8274/9/2024
3.18643 % Kuhn (Thomas)1,693,07280,0004/28/2023
0.40573 % Poxel SA Employees215,580215,58012/31/2022
0 % ACA Asset management Company & Associés0-26,0003/31/2023
0 % Consultinvest Asset Management SGR S.p.A.0-150,0003/31/2023
0 % Etoile Gestion S.A.0-26,4448/31/2022
0 % LBP AM0-42,6457/31/2022
0 % State Street Global Advisors (US)0-32,3619/30/2022
1

Poxel Executives and Management Board

Mr. Thomas Kuhn
Poxel Chief Executive Officer, Director
Compensation 403,895
Mr. Richard Kender67
Poxel Independent Director
Compensation 108,061
Mr. Mohammed Baluch
Poxel Chairman of the Board
Compensation 105,061
Ms. Pascale Boissel
Poxel Independent Director
Compensation 74,000
Dr. Sebastien Bolze
Poxel Chief Operating Officer, Executive Vice President in charge of Project Management, Non Clinical and Manufacturing operations (since 2019)
1
2
3

Poxel Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Roivant Sciences Stock
Roivant Sciences
SupplierCustomer0,350,150,880,850,82-
Merck Stock
Merck
SupplierCustomer0,110,300,080,83-0,04-0,53
Sumitomo Pharma Stock
Sumitomo Pharma
SupplierCustomer-0,640,120,360,840,860,44
1

Most common questions regarding Poxel

What values and corporate philosophy does Poxel represent?

Poxel SA represents a strong set of values and corporate philosophy. The company is committed to driving innovation and advancing scientific research in the field of metabolic disorders. Poxel SA prioritizes integrity, professionalism, and collaboration, which are embodied in its dedicated team and partnerships. With a focus on patient-centricity, Poxel SA strives to develop effective treatments for serious conditions like type 2 diabetes and non-alcoholic steatohepatitis. By leveraging its expertise and leveraging cutting-edge technologies, Poxel SA aims to make a positive impact on patients' lives worldwide.

In which countries and regions is Poxel primarily present?

Poxel SA is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, with a focus on France, Germany, and Italy. Additionally, Poxel SA operates in North America, particularly in the United States. The company also has a presence in Asia, with key markets including Japan and South Korea. With its global outreach, Poxel SA is constantly expanding its geographical footprint to reach more markets and serve a broader customer base.

What significant milestones has the company Poxel achieved?

Poxel SA, a renowned French biopharmaceutical company, has accomplished significant milestones in its journey. Notably, Poxel SA successfully completed the Phase 3 trials for its lead product, Imeglimin, a potential groundbreaking treatment for type 2 diabetes. Additionally, the company received positive feedback from regulatory authorities, advancing its development plans globally. Furthermore, Poxel SA secured strategic partnerships and collaborations with esteemed organizations to enhance its research and development efforts. These achievements demonstrate Poxel SA's dedication to revolutionizing healthcare through innovative therapies.

What is the history and background of the company Poxel?

Poxel SA is a pharmaceutical company specializing in the development of innovative treatments for metabolic diseases. Founded in 2009, the company is headquartered in Lyon, France. Poxel focuses on developing drugs that address unmet medical needs in areas such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company's research and development efforts are supported by a robust pipeline and collaborations with renowned academic institutions and strategic partners. Poxel's mission is to improve the lives of patients worldwide by providing effective therapeutic solutions. With its commitment to scientific excellence and patient-centric approach, Poxel is at the forefront of advancing treatments for metabolic diseases.

Who are the main competitors of Poxel in the market?

The main competitors of Poxel SA in the market include pharmaceutical companies such as Novo Nordisk, Sanofi, and Eli Lilly.

In which industries is Poxel primarily active?

Poxel SA is primarily active in the pharmaceutical industry.

What is the business model of Poxel?

The business model of Poxel SA revolves around the development and commercialization of innovative drugs to treat metabolic disorders. Poxel SA focuses on the discovery and development of safe and effective therapeutic solutions for diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). By leveraging their expertise in mitochondrial metabolism, the company aims to offer advanced treatment options to patients worldwide. Poxel SA also seeks to collaborate with strategic partners and leverage their partnerships to advance the development of its product portfolio. Through its dedicated efforts, Poxel SA strives to improve the lives of individuals affected by metabolic disorders.

What is the P/E ratio of Poxel 2024?

The Poxel P/E ratio is -0.16.

What is the P/S ratio of Poxel 2024?

The Poxel P/S ratio is 0.17.

What is the AlleAktien quality score of Poxel?

The AlleAktien quality score for Poxel is 4/10.

What is the revenue of Poxel 2024?

The expected Poxel revenue is 58.5 M EUR.

How high is the profit of Poxel 2024?

The expected Poxel profit is -62.66 M EUR.

What is the business model of Poxel

Poxel SA is a French biopharmaceutical company focused on developing and marketing groundbreaking therapeutics for the treatment of metabolic diseases. The company collaborates closely with prominent academic institutions and research facilities worldwide to develop innovative solutions aimed at improving patients' quality of life. The company offers a wide range of products, including Imeglimin, a novel molecule that improves mitochondrial function and increases insulin sensitivity in the body. Imeglimin aims to treat type 2 diabetes and other metabolic diseases by directly acting on the insulin sensitivity of cells. Another important product of Poxel SA is PXL770, a small molecule that stimulates the AMPK signaling pathway. This improves insulin sensitivity and can help combat obesity and other metabolic diseases. The company has also entered into a collaboration with Roivant Sciences to develop a treatment program for non-alcoholic steatohepatitis (NASH). This involves testing a compound called PXL065, which is intended to act in the liver and could help reduce inflammation and fibrosis. To finance the development and marketing of these products, Poxel SA utilizes a unique business model that is based on collaboration with strategic partners, as well as clinical studies and licenses. The company works closely with leading players in the pharmaceutical industry to develop and market its products. Through licensing agreements and the sale of research and development to partner companies, the company can bring its products to market and simultaneously finance its research and development activities. Furthermore, Poxel SA employs innovative business models to accelerate the development and marketing of its products. The company is heavily involved in the research and development efforts of its partners, utilizing state-of-the-art scientific methods and technologies. The company also collaborates closely with academic institutions and research facilities to develop new therapies and technologies targeting metabolic diseases. Overall, Poxel SA is an innovative company focused on the development and marketing of metabolic therapies. Through collaboration with other pharmaceutical companies and academic institutions, the company is able to bring its products to market, finance its research and development, and improve the quality of life for patients worldwide.

What is the Poxel dividend?

Poxel pays a dividend of 0 EUR distributed over payouts per year.

How often does Poxel pay dividends?

The dividend cannot currently be calculated for Poxel or the company does not pay out a dividend.

What is the Poxel ISIN?

The ISIN of Poxel is FR0012432516.

What is the Poxel WKN?

The WKN of Poxel is A14M04.

What is the Poxel ticker?

The ticker of Poxel is POXEL.PA.

How much dividend does Poxel pay?

Over the past 12 months, Poxel paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Poxel is expected to pay a dividend of 0 EUR.

What is the dividend yield of Poxel?

The current dividend yield of Poxel is .

When does Poxel pay dividends?

Poxel pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Poxel?

Poxel paid dividends every year for the past 0 years.

What is the dividend of Poxel?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Poxel located?

Poxel is assigned to the 'Health' sector.

Wann musste ich die Aktien von Poxel kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Poxel from 10/4/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Poxel pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Poxel in the year 2023?

In the year 2023, Poxel distributed 0 EUR as dividends.

In which currency does Poxel pay out the dividend?

The dividends of Poxel are distributed in EUR.

All fundamentals about Poxel

Our stock analysis for Poxel Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Poxel Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.